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Hangovers are associated with negative economic consequences due to decreased job performance or
frequent visits to physicians. Thus, a new strategy for the alleviation of hangover-related symptoms is
needed to avoid this detriment to society. The purpose of this nationwide randomized, double-blind,
placebo-controlled physicians’ trial was to evaluate the efficacy of loxoprofen sodium for the allevia-
tion of fatigue, headache, and nausea after hangover. A total of 229 participants were randomized to
receive loxoprofen sodium (60 mg once orally) or placebo. The study was closed when the first 150
participants (n ¼ 74 in the loxoprofen vs. n ¼ 76 in the placebo groups) experienced hangovers. The
primary endpoint was set as the difference in severity of general fatigue before and 3 h after taking the
test drugs and was evaluated using a visual analogue scale. Secondary endpoints included difference in
severity of headache, nausea, and incidence of adverse events. The study participants were 34 (inter-
quartile range; 30e39) years old, 92.0% were men, and both groups were comparable for baseline
characteristics. The alleviation of general fatigue did not differ statistically between the loxoprofen and
placebo groups (24 [14e49] vs. 19 [9e35], p ¼ 0.07). However, the alleviation of headache was statis-
tically greater in the loxoprofen group (25 [10e50] vs. 10 [2e30], adjusted difference 14, 95% confidence
interval 8e21, p < 0.001), whereas, there was no difference in nausea (7 [0e27] vs. 10 [0e24], p ¼ 0.68).
The incidence of adverse symptoms such as epigastric discomfort was also comparable between groups
(2.7% vs. 3.9%, p ¼ 0.25). Loxoprofen sodiumwas effective for relieving headaches after hangovers but did
not alleviate general fatigue or nausea.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
An alcohol hangover is composed of a set of disturbing symp-
toms, such as headache and nausea, the day after drinking excessivevestigation, Japan Society of
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Inc. This is an open access article ualcohol (Jayawardena, Thejani, Ranasinghe, Fernando, & Verster,
2017; Pittler, Verster, & Ernst, 2005; Verster & Penning, 2010).
Some physicians also include fatigue as a hangover-related symp-
tom (Verster & Penning, 2010). A hangover is associated with
negative economic consequences due to decreased job perfor-
mance or frequent presentation for medical care. Therefore, eval-
uating a new strategy for the alleviation of these hangover-related
symptoms may aid in avoiding its detrimental effects on society
(Frone, 2006; Hindmarch, Land,&Wright, 2012; Jayawardena et al.,
2017; Perez, Keijzers, Steele, Byrnes,& Scuffham, 2013; Pittler et al.,
2005; Verster & Penning, 2010). However, there is no consensusnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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symptoms despite some data with respect to the efficacy of pro-
phylaxis being available (Frone, 2006; Hindmarch et al., 2012;
Jayawardena et al., 2017; Perez et al., 2013; Pittler et al., 2005;
Verster & Penning, 2010). In contrast, a web-based questionnaire
circulated by one of the most popular commercial medical journals
in Japan (Nikkei Medical, Tokyo, Japan) was completed by 2739
medical doctors and revealed that approximately 17.1% of re-
spondents themselves take nonsteroidal anti-inflammatory drugs
(NSAIDs) empirically to alleviate hangover symptoms (Tajima,
2015). It is intuitively understandable that cyclooxygenase
blockage and the resultant inhibition of prostaglandin synthesis
may relieve some of the symptoms of a hangover, considering that
alcohol metabolites, such as acetaldehyde, can provoke inflamma-
tion that may be associated with some of these symptoms (Brooks
& Day, 1991; Jayawardena et al., 2017; Kaivola, Parantainen,
Osterman, & Timonen, 1983; Ong, Lirk, Tan, & Seymour, 2007).
The purpose of this nationwide randomized, double-blind, placebo-
controlled physicians’ trial was to evaluate the efficacy of lox-
oprofen sodium for the alleviation of fatigue, headache, and nausea
after hangover. Our experimental hypothesis was that loxoprofen
sodium is effective for relieving headache, slightly effective for
general fatigue, and ineffective for nausea.
Methods
Study design
This study was designed as a nationwide, randomized, double-
blind, placebo-controlled physicians’ trial. The flowchart of partic-
ipant selection is shown in Fig. 1. Participants were recruited using
social networking service (SNS) announcements via Facebook and
Twitter, and through Yahoo! JAPAN and Nikkei Medical from
August 2017 to May 2018. After voluntary web-based submissions
from the participants, we issued identification (ID) to each partic-
ipant for the use of electronic data capture (EDC). Then, the par-
ticipants were asked to provide their informed consent and to
submit basic personal information, which was followed by our in-
ternal review to check whether they met the inclusion and exclu-
sion criteria. The pre-specified inclusion and exclusion criteria are
shown in Supplementary Table 1. In summary, participants were
recruited for the trial if they were medical doctors in Japan who
could drink alcohol and might experience hangovers during the
study period and had read and agreed to the study concept, design,
and protocols in a web-based informed consent form. Participants
were excluded from the trial if they had any significant medical
history or past complications associated with an increased risk of
adverse events, such as a history of peptic ulcer or routine usage of
NSAIDs. When the participants completed data input on the EDC
andmet the pre-specified criteria, they were randomized to receive
either loxoprofen sodium (60 mg once orally, Loxonin®, Daiichi-
Sankyo, Tokyo, Japan) or placebo, in a gender-stratified 1:1
manner. The test drugs were delivered to their institutions, and
they were expected to take them whenever they experienced
general fatigue related to a hangover. The symptoms before and 3 h
after taking the medicine were recorded on the EDC. The study was
led by the Japan Society of Clinical Research (JSCR). The study
protocol, which complied with the standards outlined in the
Declaration of Helsinki, was approved by the Institutional Review
Board of the JSCR (approval number 201702), and was registered to
the University Hospital Medical Information Network-Clinical Trials
Registry (UMIN-CTR, Clinical Trial Registration Number
UMIN000028441 01/08/2017, Hangovercome Study) which is
certified by the International Committee of Medical Journal Editors
(ICMJE).Endpoint and sample size calculation
The primary endpoint was set as the difference in severity of
general fatigue before and 3 h after taking the test drugs. Secondary
endpoints included difference in the severity of headache and
nausea before and 3 h after taking the test drugs, and incidence of
an adverse event. These symptoms were evaluated using a visual
analogue scale (VAS) rating system with no symptoms taken to be
0 mm, placed at the left end of the VAS line, and the worst symp-
toms as 100 mm at the right end of the VAS line. Based on the drug
information, according to which the time to maximum concen-
tration of loxoprofen sodium in the blood is 0.45 h after the oral
administration and its half-life is 1.22 h among healthy volunteers,
we set the timing of symptom evaluation at 3 h after the test drug
administration.
Sample size was determined based on the following estimates
and indices: (1) the difference in the severity of the primary
endpoint between the loxoprofen and placebo groups was esti-
mated to be greater than 7 mm on the VAS rating system, (2) the
standard deviation of the difference in severity of the primary
endpoint was estimated to be 13.79 mm based on the preliminary
web-based questionnaire, and (3) the statistical significance was
evaluated using a t test with a two-sided significance level of 0.05
and a statistical power of 0.80. In each group, 62 participants were
needed to satisfy the above statistical requirements and we set the
final sample size at 75 participants in each group, considering a
maximum of 17.5% risk of inaccurate data input because of the
symptoms of a hangover. In addition, we decided to continue the
entries for the study until the number of randomization partici-
pants reached was 500 (250 in each group), because not all par-
ticipants necessarily experienced a hangover during the study
period (Fig. 1). Our pre-specified study completion point occurred
when 150 participants experienced hangovers, took test drugs, and
completed the EDC data input without any missing data. At this
time point, the EDC was closed and an announcement that the
study was complete was made by sending e-mails as well as
through SNS announcements.
Statistical analysis
Continuous variables were summarized using the median with
1st and 3rd quartiles. Categorical variables were summarized using
frequencies with percentages. The difference in the effects of the
treatment was analyzed by the linear regression model. In this
model, the explained variable was the score of the VAS rating
system at 3 h after the drug administration, and the explanatory
variables were treatment with the drug, participant's sex, and VAS
score before the drug administration. Fisher's exact test was
applied to evaluate the independence of incidence of adverse
events between the loxoprofen and placebo groups. There were no
missing data in the present study. The significance level for our
statistical analysis was set at 0.05 with the two-sided alternative
hypothesis as the primary endpoint. p values for the results of hy-
pothesis testing for the secondary endpoints were evaluated by the
Bonferroni adjustment for multiplicity of the tests, and the signif-
icance level was set at 0.017. All statistical analyses were performed
using the R software (version 3.4.2).
Results
The flowchart of participant selection and final study population
for statistical analysis is shown in Fig. 1. During the study period, a
total of 320 participants completed the web-based entry, and 297
were issued ID for EDC usage. After excluding 9 disqualified par-
ticipants and 59 participants who did not complete the basic
Fig. 1. Flowchart of participant selection. EDC, electronic data capture; ID, identification; MD, medical doctor
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loxoprofen sodium and the placebo groups, in a sex-stratified 1:1
fashion. Finally, 150 participants (n ¼ 74 in the loxoprofen group vs.
n ¼ 76 in the placebo group) experienced hangovers, took the test
drugs, and completed the data input. The geographical distribution
and specialty of participants are shown in Supplementary Fig. 1 and
Supplementary Table 2, respectively.
Participant characteristics are shown in Table 1. Study partici-
pants were 34 (interquartile range; 30e39) years old and 92.0%
were men. Four (2.7%) participants took routine medication that
might have interacted with loxoprofen sodium, and 45.3% worked
at the University. Approximately 40% of the participants had ever
used loxoprofen sodium for the alleviation of the symptoms related
to a hangover, and more than 50% of them thought that it was
effective for general fatigue, more than 90% for headache, and more
than 20% of participants thought it was effective for nausea. Median
water intake after drug administration was 300 (200e500) mL.
Both groups were comparable for baseline characteristics (Table 1).
With respect to the hangover symptoms shown in Table 2,
alleviation of general fatigue did not differ statistically between the
loxoprofen and the placebo groups (24 [14e49] vs. 19 [9e35],
adjusted difference 6, 95% confidence interval [CI] 0.49e13,p ¼ 0.07). However, the rate of alleviation of headache was statis-
tically greater in the loxoprofen group than in the placebo group
(25 [10e50] vs. 10 [2e30], adjusted difference 14, 95% CI 8e21,
p < 0.001), whereas that of nausea was not statistically different (7
[0e27] vs. 10 [0e24], adjusted difference 1, 95% CI 6e4,
p¼ 0.68). The incidence of adverse symptoms was also comparable
between the loxoprofen and placebo groups, with two participants
with epigastric discomfort reported in the loxoprofen group, two
participants with stomach aches, and one with a feeling of a loose
tooth were reported in the placebo group (p ¼ 0.25) (Table 2).
Discussion
In this nationwide randomized, double-blind, placebo-
controlled physicians’ trial of loxoprofen sodium for the alleviation
of the symptoms after a hangover, we demonstrated that (1) sta-
tistically, loxoprofen sodium did not alleviate general fatigue or
nausea symptoms when compared to placebo, whereas loxoprofen
was significantly effective for relieving headache, even after ad-
justments for sex and baseline severities of symptoms were made;
and (2) the incidence of adverse events was comparable between
the loxoprofen and placebo groups.
Table 1
Participants’ backgrounds.
Parameter Total (n ¼ 150) Loxoprofen (n ¼ 74) Placebo (n ¼ 76)
Age, years 34 (30e39) 33 (30e37) 35 (32e40)
Male 138 (92.0) 68 (91.9) 70 (92.1)
Height, cm 171 (167e175) 172 (168e175) 171 (167e175)
Weight, kg 67 (61e73) 67 (62e72) 66 (60e73)
Medication with possible interaction with loxoprofen sodium 4 (2.7) 3 (4.1) 1 (1.3)
ACEI or ARB 4 (2.7) 3 (4.1) 1 (1.3)
Thiazide 1 (0.7) 1 (1.4) 0 (0.0)
Work at University 68 (45.3) 35 (47.3) 33 (43.4)
Expectation of study drug
Identified 20 (13.3) 10 (13.5) 10 (13.2)
Non-identified, including unknown 130 (86.7) 64 (86.5) 66 (86.8)
Experience in using loxoprofen for managing symptoms of hangover 64 (42.7) 33 (44.6) 31 (40.8)
Believe it is effective for fatigue 36 (56.3) 17 (51.5) 19 (61.3)
Believe it is effective for headache 58 (90.6) 30 (90.9) 28 (90.3)
Believe it is effective for nausea 13 (20.3) 8 (24.2) 5 (16.1)
Alcohol (multiple selection)
Beer 133 (88.7) 65 (87.8) 68 (89.5)
Wine 55 (36.7) 30 (40.5) 25 (32.9)
Whisky or brandy 39 (26.0) 18 (24.3) 21 (27.6)
Japanese sake 57 (38.0) 29 (39.2) 28 (36.8)
Japanese shochu 25 (16.7) 12 (16.2) 13 (17.1)
Others, including cocktails 22 (14.7) 9 (12.2) 13 (17.1)
Water intake after study drug administration, mL 300 (200e500) 300 (200e500) 300 (150e500)
Continuous variables were summarized using the median with 1st and 3rd quartiles in parentheses. Categorical variables were summarized by frequencies with percentages
in parentheses. The following drugs are listed as drugs that may interact with NSAIDs according to drug information: warfarin, ACEI or ARB, new quinolones, methotrexate,
lithium, thiazide, and sulfonylurea.
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker
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As there is no consensus about the effective treatment protocol
for the alleviation of the symptoms of a hangover, despite some
data with respect to the efficacy of prophylaxis being available, our
results confirmed that loxoprofen can be used for headache relief,
although it was already empirically known by 17.1% of physicians
based on a web-based questionnaire, as mentioned in the intro-
duction (Frone, 2006; Hindmarch et al., 2012; Jayawardena et al.,
2017; Kaivola et al., 1983; Perez et al., 2013; Pittler et al., 2005;
Tajima, 2015; Verster & Penning, 2010). There is a wide range of
symptoms associated with a hangover, and many possible mecha-
nisms have been suggested for these symptoms (Frone, 2006;
Hindmarch et al., 2012; Jayawardena et al., 2017; Kaivola et al.,
1983; Perez et al., 2013; Pittler et al., 2005; Tajima, 2015; Verster
& Penning, 2010). Our experimental hypothesis was thatTable 2
Primary and secondary endpoints of hangover.
Parameter Loxoprofen (n ¼ 74) Placebo (n ¼ 76) p value
General Fatigue
Pre 70 (59e75) 70 (60e80) e
3 h later 30 (17e60) 50 (20e60) e
Delta 24 (14e49) 19 (9e35) 0.07
Headache
Pre 60 (26e71) 54 (24e70) e
3 h later 10 (0e31) 24 (0e58) e
Delta 25 (10e50) 10 (2e30) <0.001
Nausea
Pre 25 (1e60) 30 (10e60) e
3 h later 9 (0e24) 7 (0e34) e
Delta 7 (0e27) 10 (0e24) 0.68
Adverse Symptoms 0.25
Stomach ache 0 (0.0) 2 (2.6) e
Epigastric discomfort 2 (2.7) 0 (0.0) e
Feeling of loose tooth 0 (0.0) 1 (1.3) e
Continuous variables were summarized using median with 1st and 3rd quartiles in
parentheses. Categorical variables were summarized by frequencies with percent-
ages in parentheses.loxoprofen sodium is effective for relieving headache, slightly
effective for general fatigue, and ineffective for nausea. This hy-
pothesis was developed empirically, considering that cyclo-
oxygenase blockage and the resultant inhibition of prostaglandin
synthesis can relieve hangover symptoms provoked by inflamma-
tion due to alcohol metabolites, although there is no strong scien-
tific evidence regarding possible mechanisms for the pathology of
alcohol hangover (Brooks & Day, 1991; Jayawardena et al., 2017;
Kaivola et al., 1983; Ong et al., 2007; Verster & Penning, 2010).
However, according to our results, loxoprofen sodium was only
effective for headaches. This is partly because of multiple physio-
logical mechanisms responsible for causing hangovers, such as
those associated with metabolism of alcohol itself or the oxidative
damage caused by the free radicals associated with excessive
alcohol consumption (Jayawardena et al., 2017; Pittler et al., 2005;
Verster & Penning, 2010). Even though our study first revealed that
loxoprofen sodium is effective to alleviate headaches during a
hangover, it is important to remember that we do not intend to
recommend alcohol consumption through this study, and that the
misuse of alcohol is an important issue that should be discussed
with respect to interventions such as behavioral counseling (U.S.
Preventive Services Task Force, 2004).
Clinical implications
When implementing a new treatment strategy in medicine, we
must think about the balance of therapeutic efficacy, safety, cost,
and the overall effect of the treatment on the economy of the
country. We showed that loxoprofen sodium showed statistically
more alleviation of headache than placebo, 3 h after the adminis-
tration of the drug. The incidence of adverse events was 2.7% in this
study, and was a transient epigastric discomfort. Even without
definite evidence regarding the incidence of adverse events of a
single dose of NSAIDs in healthy non-risk populations, adverse
events are assumed to be minimal for loxoprofen sodium, which is
a derivative of propionic acid, which includes ibuprofen (Ong et al.,
2007; Rollason, Samer, Daali, & Desmeules, 2014). The familiarity
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may also ensure the safe usage of this drug (Ong et al., 2007;
Rollason et al., 2014). In addition, the cost of loxoprofen sodium
(60 mg) was less than $0.50 per tablet. With respect to the adverse
economic effects of a hangover, it was reported that approximately
$2000 per employee are lost annually because of alcohol-related
absenteeism and impaired working ability in the United States
(Jayawardena et al., 2017; Verster & Penning, 2010). With these
points of view, we think that the health and economic benefits
outweigh the potential harm of treating headaches due to hang-
overs using NSAIDs. This strategy for alleviation of headaches due
to hangovers using NSAIDs may, at least in part, contribute to
avoiding the detriment to society associated with negative eco-
nomic consequences due to decreased job performance or frequent
presentation to a health care provider (Frone, 2006; Hindmarch
et al., 2012; Jayawardena et al., 2017; Perez et al., 2013; Pittler
et al., 2005; Verster & Penning, 2010).
Study limitations
Our study has some limitations that warrant mention. First,
the difference in the effects of loxoprofen sodium as a treatment
for hangover-related symptoms with respect to the sex of the
participants could not be determined because less than 10% of
the participants enrolled in this study were women. Second, it is
possible that a dose of 60 mg by oral administration may be a
minimal dose and that high dose administration may lead to
different results. Third, it is possible that evaluation at 1 or 2 h
after the test drug administration may also lead to different
results, considering the rapid absorption and fast metabolic
pharmacokinetics of loxoprofen sodium. Fourth, variation in
therapeutic and adverse responses of different NSAIDs has been
reported, and it is unclear whether our results with loxoprofen
sodium can be applied to other NSAIDs (Fries et al., 2006;
Rollason et al., 2014). Fifth, there is no strong scientific evi-
dence regarding possible mechanisms for the pathology of
alcohol hangover, and the most important theories are the au-
thors’ hypotheses, not a consensus in the field (Verster &
Penning, 2010). Sixth, due to a problem of multiplicity of the
statistical tests and the above-mentioned lack of pathological
evidence, we wanted to minimize the number of endpoints as
much as possible. This led to a narrow focus on hangover
symptoms. Lastly, amount of alcohol consumption or genetic
susceptibility for alcohol were not evaluated. However, lack of
these measurements is not of great importance because the
merit of randomized controlled trial is to balance all con-
founding factors regardless of measurability. Thus, we believe
that a nationwide randomized, double-blind, placebo-controlled
trial with comparable baseline characteristics between the lox-
oprofen and placebo groups outweighs these limitations.
Conclusions
This nationwide randomized, double-blind, placebo-controlled
physicians’ trial demonstrated that loxoprofen sodium was effec-
tive for relieving headache during a hangover but did not alleviate
general fatigue or nausea.
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